

Sequence Listing

<110> De Sauvage, Frederic
Grewal, Iqbal
Gurney, Austin L.

<120> TYPE I CYTOKINE RECEPTOR TCCR

<130> P1748R1E

<140> US 10/088,950

<141> 2002-10-20

<150> US 60/160,542

<151> 1999-10-20

<150> PCT/US00/28827

<151> 2000-10-18

<160> 16

<210> 1

<211> 636

<212> PRT

<213> Homo sapiens

<400> 1

Met	Arg	Gly	Gly	Arg	Gly	Ala	Pro	Phe	Trp	Leu	Trp	Pro	Leu	Pro	
1				5					10					15	
Lys	Leu	Ala	Leu	Leu	Pro	Leu	Leu	Trp	Val	Leu	Phe	Gln	Arg	Thr	
				20					25					30	
Arg	Pro	Gln	Gly	Ser	Ala	Gly	Pro	Leu	Gln	Cys	Tyr	Gly	Val	Gly	
				35					40					45	
Pro	Leu	Gly	Asp	Leu	Asn	Cys	Ser	Trp	Glu	Pro	Leu	Gly	Asp	Leu	
				50					55					60	
Gly	Ala	Pro	Ser	Glu	Leu	His	Leu	Gln	Ser	Gln	Lys	Tyr	Arg	Ser	
				65					70					75	
Asn	Lys	Thr	Gln	Thr	Val	Ala	Val	Ala	Ala	Gly	Arg	Ser	Trp	Val	
				80					85					90	

Ala	Ile	Pro	Arg	Glu	Gln	Leu	Thr	Met	Ser	Asp	Lys	Leu	Leu	Val
				95					100					105
Trp	Gly	Thr	Lys	Ala	Gly	Gln	Pro	Leu	Trp	Pro	Pro	Val	Phe	Val
				110					115					120
Asn	Leu	Glu	Thr	Gln	Met	Lys	Pro	Asn	Ala	Pro	Arg	Leu	Gly	Pro
				125					130					135
Asp	Val	Asp	Phe	Ser	Glu	Asp	Asp	Pro	Leu	Glu	Ala	Thr	Val	His
				140					145					150
Trp	Ala	Pro	Pro	Thr	Trp	Pro	Ser	His	Lys	Val	Leu	Ile	Cys	Gln
				155					160					165
Phe	His	Tyr	Arg	Arg	Cys	Gln	Glu	Ala	Ala	Trp	Thr	Leu	Leu	Glu
				170					175					180
Pro	Glu	Leu	Lys	Thr	Ile	Pro	Leu	Thr	Pro	Val	Glu	Ile	Gln	Asp
				185					190					195
Leu	Glu	Leu	Ala	Thr	Gly	Tyr	Lys	Val	Tyr	Gly	Arg	Cys	Arg	Met
				200					205					210
Glu	Lys	Glu	Glu	Asp	Leu	Trp	Gly	Glu	Trp	Ser	Pro	Ile	Leu	Ser
				215					220					225
Phe	Gln	Thr	Pro	Pro	Ser	Ala	Pro	Lys	Asp	Val	Trp	Val	Ser	Gly
				230					235					240
Asn	Leu	Cys	Gly	Thr	Pro	Gly	Gly	Glu	Glu	Pro	Leu	Leu	Leu	Trp
				245					250					255
Lys	Ala	Pro	Gly	Pro	Cys	Val	Gln	Val	Ser	Tyr	Lys	Val	Trp	Phe
				260					265					270
Trp	Val	Gly	Gly	Arg	Glu	Leu	Ser	Pro	Glu	Gly	Ile	Thr	Cys	Cys
				275					280					285
Cys	Ser	Leu	Ile	Pro	Ser	Gly	Ala	Glu	Trp	Ala	Arg	Val	Ser	Ala
				290					295					300
Val	Asn	Ala	Thr	Ser	Trp	Glu	Pro	Leu	Thr	Asn	Leu	Ser	Leu	Val
				305					310					315

Cys	Leu	Asp	Ser	Ala	Ser	Ala	Pro	Arg	Ser	Val	Ala	Val	Ser	Ser	320	325	330
Ile	Ala	Gly	Ser	Thr	Glu	Leu	Leu	Val	Thr	Trp	Gln	Pro	Gly	Pro	335	340	345
Gly	Glu	Pro	Leu	Glu	His	Val	Val	Asp	Trp	Ala	Arg	Asp	Gly	Asp	350	355	360
Pro	Leu	Glu	Lys	Leu	Asn	Trp	Val	Arg	Leu	Pro	Pro	Gly	Asn	Leu	365	370	375
Ser	Ala	Leu	Leu	Pro	Gly	Asn	Phe	Thr	Val	Gly	Val	Pro	Tyr	Arg	380	385	390
Ile	Thr	Val	Thr	Ala	Val	Ser	Ala	Ser	Gly	Leu	Ala	Ser	Ala	Ser	395	400	405
Ser	Val	Trp	Gly	Phe	Arg	Glu	Glu	Leu	Ala	Pro	Leu	Val	Gly	Pro	410	415	420
Thr	Leu	Trp	Arg	Leu	Gln	Asp	Ala	Pro	Pro	Gly	Thr	Pro	Ala	Ile	425	430	435
Ala	Trp	Gly	Glu	Val	Pro	Arg	His	Gln	Leu	Arg	Gly	His	Leu	Thr	440	445	450
His	Tyr	Thr	Leu	Cys	Ala	Gln	Ser	Gly	Thr	Ser	Pro	Ser	Val	Cys	455	460	465
Met	Asn	Val	Ser	Gly	Asn	Thr	Gln	Ser	Val	Thr	Leu	Pro	Asp	Leu	470	475	480
Pro	Trp	Gly	Pro	Cys	Glu	Leu	Trp	Val	Thr	Ala	Ser	Thr	Ile	Ala	485	490	495
Gly	Gln	Gly	Pro	Pro	Gly	Pro	Ile	Leu	Arg	Leu	His	Leu	Pro	Asp	500	505	510
Asn	Thr	Leu	Arg	Trp	Lys	Val	Leu	Pro	Gly	Ile	Leu	Phe	Leu	Trp	515	520	525
Gly	Leu	Phe	Leu	Leu	Gly	Cys	Gly	Leu	Ser	Leu	Ala	Thr	Ser	Gly	530	535	540

Arg	Cys	Tyr	His	Leu	Arg	His	Lys	Val	Leu	Pro	Arg	Trp	Val	Trp
				545					550					555
Glu	Lys	Val	Pro	Asp	Pro	Ala	Asn	Ser	Ser	Ser	Gly	Gln	Pro	His
				560					565					570
Met	Glu	Gln	Val	Pro	Glu	Ala	Gln	Pro	Leu	Gly	Asp	Leu	Pro	Ile
				575					580					585
Leu	Glu	Val	Glu	Glu	Met	Glu	Pro	Pro	Pro	Val	Met	Glu	Ser	Ser
				590					595					600
Gln	Pro	Ala	Gln	Ala	Thr	Ala	Pro	Leu	Asp	Ser	Gly	Tyr	Glu	Lys
				605					610					615
His	Phe	Leu	Pro	Thr	Pro	Glu	Glu	Leu	Gly	Leu	Leu	Gly	Pro	Pro
				620					625					630
Arg	Pro	Gln	Val	Leu	Ala									
				635										

<210> 2

<211> 623

<212> PRT

<213> Mus musculus

<400> 2

Met	Asn	Arg	Leu	Arg	Val	Ala	Arg	Leu	Thr	Pro	Leu	Glu	Leu	Leu
1				5					10					15
Leu	Ser	Leu	Met	Ser	Leu	Leu	Leu	Gly	Thr	Arg	Pro	His	Gly	Ser
				20					25					30
Pro	Gly	Pro	Leu	Gln	Cys	Tyr	Ser	Val	Gly	Pro	Leu	Gly	Ile	Leu
				35					40					45
Asn	Cys	Ser	Trp	Glu	Pro	Leu	Gly	Asp	Leu	Glu	Thr	Pro	Pro	Val
				50					55					60
Leu	Tyr	His	Gln	Ser	Gln	Lys	Tyr	His	Pro	Asn	Arg	Val	Trp	Glu
				65					70					75
Val	Lys	Val	Pro	Ser	Lys	Gln	Ser	Trp	Val	Thr	Ile	Pro	Arg	Glu
				80					85					90

Gln	Phe	Thr	Met	Ala	Asp	Lys	Leu	Leu	Ile	Trp	Gly	Thr	Gln	Lys
				95					100					105
Gly	Arg	Pro	Leu	Trp	Ser	Ser	Val	Ser	Val	Asn	Leu	Glu	Thr	Gln
				110					115					120
Met	Lys	Pro	Asp	Thr	Pro	Gln	Ile	Phe	Ser	Gln	Val	Asp	Ile	Ser
				125					130					135
Glu	Glu	Ala	Thr	Leu	Glu	Ala	Thr	Val	Gln	Trp	Ala	Pro	Pro	Val
				140					145					150
Trp	Pro	Pro	Gln	Lys	Ala	Leu	Thr	Cys	Gln	Phe	Arg	Tyr	Lys	Glu
				155					160					165
Cys	Gln	Ala	Glu	Ala	Trp	Thr	Arg	Leu	Glu	Pro	Gln	Leu	Lys	Thr
				170					175					180
Asp	Gly	Leu	Thr	Pro	Val	Glu	Met	Gln	Asn	Leu	Glu	Pro	Gly	Thr
				185					190					195
Cys	Tyr	Gln	Val	Ser	Gly	Arg	Cys	Gln	Val	Glu	Asn	Gly	Tyr	Pro
				200					205					210
Trp	Gly	Glu	Trp	Ser	Ser	Pro	Leu	Ser	Phe	Gln	Thr	Pro	Phe	Leu
				215					220					225
Asp	Pro	Glu	Asp	Val	Trp	Val	Ser	Gly	Thr	Val	Cys	Glu	Thr	Ser
				230					235					240
Gly	Lys	Arg	Ala	Ala	Leu	Leu	Val	Trp	Lys	Asp	Pro	Arg	Pro	Cys
				245					250					255
Val	Gln	Val	Thr	Tyr	Thr	Val	Trp	Phe	Gly	Ala	Gly	Asp	Ile	Thr
				260					265					270
Thr	Thr	Gln	Glu	Glu	Val	Pro	Cys	Cys	Lys	Ser	Pro	Val	Pro	Ala
				275					280					285
Trp	Met	Glu	Trp	Ala	Val	Val	Ser	Pro	Gly	Asn	Ser	Thr	Ser	Trp
				290					295					300
Val	Pro	Pro	Thr	Asn	Leu	Ser	Leu	Val	Cys	Leu	Ala	Pro	Glu	Ser
				305					310					315

Ala	Pro	Cys	Asp	Val	Gly	Val	Ser	Ser	Ala	Asp	Gly	Ser	Pro	Gly	320	325	330
Ile	Lys	Val	Thr	Trp	Lys	Gln	Gly	Thr	Arg	Lys	Pro	Leu	Glu	Tyr	335	340	345
Val	Val	Asp	Trp	Ala	Gln	Asp	Gly	Asp	Ser	Leu	Asp	Lys	Leu	Asn	350	355	360
Trp	Thr	Arg	Leu	Pro	Pro	Gly	Asn	Leu	Ser	Thr	Leu	Leu	Pro	Gly	365	370	375
Glu	Phe	Lys	Gly	Gly	Val	Pro	Tyr	Arg	Ile	Thr	Val	Thr	Ala	Val	380	385	390
Tyr	Ser	Gly	Gly	Leu	Ala	Ala	Ala	Pro	Ser	Val	Trp	Gly	Phe	Arg	395	400	405
Glu	Glu	Leu	Val	Pro	Leu	Ala	Gly	Pro	Ala	Val	Trp	Arg	Leu	Pro	410	415	420
Asp	Asp	Pro	Pro	Gly	Thr	Pro	Val	Val	Ala	Trp	Gly	Glu	Val	Pro	425	430	435
Arg	His	Gln	Leu	Arg	Gly	Gln	Ala	Thr	His	Tyr	Thr	Phe	Cys	Ile	440	445	450
Gln	Ser	Arg	Gly	Leu	Ser	Thr	Val	Cys	Arg	Asn	Val	Ser	Ser	Gln	455	460	465
Thr	Gln	Thr	Ala	Thr	Leu	Pro	Asn	Leu	His	Ser	Gly	Ser	Phe	Lys	470	475	480
Leu	Trp	Val	Thr	Val	Ser	Thr	Val	Ala	Gly	Gln	Gly	Pro	Pro	Gly	485	490	495
Pro	Asp	Leu	Ser	Leu	His	Leu	Pro	Asp	Asn	Arg	Ile	Arg	Trp	Lys	500	505	510
Ala	Leu	Pro	Trp	Phe	Leu	Ser	Leu	Trp	Gly	Leu	Leu	Leu	Met	Gly	515	520	525
Cys	Gly	Leu	Ser	Leu	Ala	Ser	Thr	Arg	Cys	Leu	Gln	Ala	Arg	Cys	530	535	540

Leu	His	Trp	Arg	His	Lys	Leu	Leu	Pro	Gln	Trp	Ile	Trp	Glu	Arg
				545					550					555
Val	Pro	Asp	Pro	Ala	Asn	Ser	Asn	Ser	Gly	Gln	Pro	Tyr	Ile	Lys
				560					565					570
Glu	Val	Ser	Leu	Pro	Gln	Pro	Pro	Lys	Asp	Gly	Pro	Ile	Leu	Glu
				575					580					585
Val	Glu	Glu	Val	Glu	Leu	Gln	Pro	Val	Val	Glu	Ser	Pro	Lys	Ala
				590					595					600
Ser	Ala	Pro	Ile	Tyr	Ser	Gly	Tyr	Glu	Lys	His	Phe	Leu	Pro	Thr
				605					610					615
Pro	Glu	Glu	Leu	Gly	Leu	Leu	Val							
				620										

<210> 3
 <211> 2646
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> 2433
 <223> unknown base

<400> 3
 gtgggttcgg cttcccgttg cgcctcgggg gctgtacca gagctcgaag 50
 aggagcagcg cggcccgcac ccggcaaggc tgggccggac tcggggctcc 100
 cgagggacgc catgcgggga ggcaggggag cccctttctg gctgtggccg 150
 ctgcccaagc tggcgctgct gcctctgttg tgggtgcttt tccagcggac 200
 gcgtccccag ggcagcgccg ggccactgca gtgctacgga gttggaccct 250
 tgggcgactt gaactgctcg tgggagcctc ttggggacct gggagcccc 300
 tccgagttac acctccagag ccaaaagtac cgttccaaca aaaccagac 350
 tgtggcagtg gcagccggac ggagctgggt ggccattcct cgggaaacagc 400
 tcaccatgtc tgacaaactc cttgtctggg gcactaaggc aggccagcct 450

ctctggcccc cegtcttcgt gaacctagaa acccaaataga agccaaacgc 500
 cccccggctg ggcctgacg tggacttttc cgaggatgac cccctggagg 550
 ccaactgtcca ttgggccccca cctacatggc catctcataa agttctgatc 600
 tgccagttcc actaccgaag atgtcaggag gcggcctgga ccctgctgga 650
 accggagctg aagaccatac ccctgacccc tgttgagatc caagatttgg 700
 agctagccac tggctacaaa gtgtatggcc gctgccggat ggagaaagaa 750
 gaggatttgt ggggcgagtg gagccccatt ttgtccttcc agacaccgcc 800
 ttctgctcca aaagatgtgt gggatatcagg gaacctctgt gggacgcctg 850
 gaggagagga acctttgctt ctatggaagg ccccagggcc ctgtgtgcag 900
 gtgagctaca aagtctgggt ctgggttgga ggtcgtgagc tgagtccaga 950
 aggaattacc tgctgctgct ccctaattcc cagtggggcg gagtgggcca 1000
 ggggtgtccgc tgtcaacgcc acaagctggg agcctctcac caacctctct 1050
 ttgggtctgct tggattcagc ctctgcccc cgtagcgtgg cagtcagcag 1100
 catcgctggg agcacggagc tactgggtgac ctggcaaccg gggcctgggg 1150
 aaccactgga gcatgtagtg gactgggctc gagatgggga cccctggag 1200
 aaactcaact ggggtccggct tccccctggg aacctcagtg ctctgttacc 1250
 aggaatttc actgtcgggg tccccatatc aatcactgtg accgcagtct 1300
 ctgcttcagg cttggcctct gcacctccg tctgggggtt caggaggaa 1350
 ttagcacccc tagtggggcc aacgctttgg cgactccaag atgcccctcc 1400
 agggaccccc gccatagcgt ggggagaggt cccaaggcac cagcttcgag 1450
 gccacctcac ccactacacc ttgtgtgcac agagtggaac cagcccctcc 1500
 gtctgcatga atgtgagtgg caacacacag agtgtcacc tgcctgacct 1550
 tccttgggggt ccctgtgagc tgtgggtgac agcatctacc atcgctggac 1600

agggccctcc tgggtcccatc ctccggcttc atctaccaga taacaccctg 1650
 aggtggaaag ttctgccggg catcctattc ttgtggggct tgttcctgtt 1700
 ggggtgtggc ctgagcctgg ccacctctgg aaggtgctac cacctaaggc 1750
 acaaagtgct gccccgctgg gtctgggaga aagttcctga tcctgccaac 1800
 agcagttcag gccagcccca catggagcaa gtacctgagg cccagccctt 1850
 tggggacttg cccatcctgg aagtggagga gatggagccc ccgccggtta 1900
 tggagtcctc ccagccccgc caggccaccg ccccgcttga ctctgggtat 1950
 gagaagcact tcctgccac acctgaggag ctgggccttc tggggccccc 2000
 caggccacag gttctggcct gaaccacacg tctggctggg ggctgccagc 2050
 caggctagag ggatgctcat gcaggttgca cccagtcct ggattagccc 2100
 tcttgatgga tgaagacact gaggactcag agaggctgag tcacttacct 2150
 gaggacccc agccaggcag agctgggatt gaaggacccc tatagagaag 2200
 ggcttggccc ccatggggaa gacacggatg gaaggtggag caaaggaaaa 2250
 tacatgaaat tgagagtggc agctgcctgc caaaatctgt tccgctgtaa 2300
 cagaactgaa tttggacccc agcacagtgg ctcacgcctg taatcccagc 2350
 actttggcag gccaaggtgg aaggatcact tagagctagg agtttgagac 2400
 cagcctgggc aatatagcaa gaccctcac tanaaaaata aaacatcaaa 2450
 aacaaaaaca attagctggg catgatggca cacacctgta gtccgagcca 2500
 cttgggaggc tgaggtggga ggatcggttg agcccaggag ttcgaagctg 2550
 caggacctc tgattgcacc actgcactcc aggctgggta acagaatgag 2600
 accttatctc aaaaataaac aaactaataa aaaaaaaaaa aaaaaa 2646

<210> 4

<211> 2005

<212> DNA

<213> Mus musculus

<400> 4

tcggttctat cgatggggcc atgaaccggc tccgggttgc acgcctcacg 50
ccgttggagc ttctgctgtc gctgatgtcg ctgctgctcg ggacgcggcc 100
ccacggcagt ccaggcccac tgcagtgtca cagcgtcggc cccctgggaa 150
tcctgaactg ctcttgggaa cctttgggag acctggagac tccacctgtg 200
ctgtatcacc agagtcagaa ataccatccc aatagagtct gggaggtgaa 250
gggtgccttcc aaacaaagtt ggggtgacct tccccgggaa cagttcacca 300
tggctgacaa actcctcatc tgggggacac aaaagggacg gcctctgtgg 350
tcctctgtct ctgtgaacct ggagacccaa atgaagccag acacacctca 400
gatcttctct caagtggata tttctgagga agcaaccctg gagggcactg 450
tgcagtgggc gccgcccgtg tggccaccgc agaaagctct cacctgtcag 500
ttccggtaca aggaatgcca ggctgaagca tggaccggc tggagcccca 550
gctgaagaca gatgggctga ctctgttga gatgcagaac ctggaacctg 600
gcacctgcta ccaggtgtct ggccgctgcc aggtggagaa cggatatcca 650
tggggcgagt ggagttcgcc cctgtccttc cagacgccat tcttagatcc 700
tgaagatgtg tgggtatcgg ggaccgtctg tgaaacttct ggcaaacggg 750
cagccctgct tgtctggaag gacccaagac cttgtgtgca ggtgacttac 800
acagtctggt ttggggctgg agatattact acaactcaag aagaggtccc 850
gtgctgcaag tcccctgtcc ctgcatggat ggagtgggct gtggtctctc 900
ctggcaacag caccagctgg gtgcctccca ccaacctgtc tctgggtgtgc 950
ttggctccag aatctgcccc ctgtgacgtg ggagtgagca gtgctgatgg 1000
gagcccaggg ataaaggtga cctggaaaca agggaccagg aaaccattgg 1050
agtatgtggt ggactgggct caagatgggt acagcctgga caagctcaac 1100
tggaccgctc tccccctgg aaacctcagc acattgttac caggggagtt 1150

caaaggaggg gtcccctatc gaattacagt gactgcagta tactctggag 1200
 gattagctgc tgcaccctca gtttggggat tcagagagga gttagtaccc 1250
 cttgctgggc cagcagtttg gcgacttcca gatgaccccc cagggacacc 1300
 tggtgtagcc tggggagaag taccaagaca ccagctcaga ggccaggcta 1350
 ctactacac cttctgcata cagagcagag gcctctccac tgtctgcagg 1400
 aacgtgagca gtcaaaccce gactgccact ctgcccaacc ttcactcggg 1450
 ttccttcaag ctgtgggtga cgggtgtccac cgttgcagga cagggcccac 1500
 ctgggtccga cctttcactt cacctaccag ataataggat caggtggaaa 1550
 gctctgccct ggtttctgtc cctgtgggggt ttgcttctga tgggctgtgg 1600
 cctgagcctg gccagtacca ggtgcctaca ggccagggtgc ttacactggc 1650
 gacacaagtt gcttccccag tggatctggg agagggttcc tgatcctgcc 1700
 aacagcaatt ctgggcaacc ttacatcaag gaggtgagcc tgccccaacc 1750
 gcccaaggac ggacccatcc tggaggtgga ggaagtggag ctacagcctg 1800
 ttgtggagtc ccctaaagcc tctgccccga tttactctgg gtatgagaaa 1850
 cacttcctgc ccacaccaga ggagctgggc cttctagtct gatctgctta 1900
 cggctagggg ctgtaccctt atcttgggct agacgttcta gagtcgaccg 1950
 cagaagcttg gccgccatgg cccaacttgt ttattgcagc ttataatgtt 2000
 aaata 2005

<210> 5
 <211> 20
 <212> DNA
 <213> Mus musculus

<400> 5
 tggtctctcc tggcaacagc 20

<210> 6
 <211> 20

<212> DNA

<213> Mus musculus

<400> 6

agccaagcac accagagaca 20

<210> 7

<211> 21

<212> DNA

<213> Mus musculus

<400> 7

cagctgggtg cctcccacca a 21

<210> 8

<211> 20

<212> DNA

<213> Mus musculus

<400> 8

atccgcaagc ctgtgactgt 20

<210> 9

<211> 18

<212> DNA

<213> Mus musculus

<400> 9

tcggggccagg gtgttttt 18

<210> 10

<211> 18

<212> DNA

<213> Mus musculus

<400> 10

ttcccggggt cgttgccg 18

<210> 11

<211> 18

<212> DNA

<213> Mus musculus

<400> 11

tcgcgtctct gggaagct 18

<210> 12
<211> 24
<212> DNA
<213> Mus musculus

<400> 12
tttaagccaa tgtatccgag actg 24

<210> 13
<211> 20
<212> DNA
<213> Mus musculus

<400> 13
cgccagcgtc ctctcgtgg 20

<210> 14
<211> 21
<212> DNA
<213> Mus musculus

<400> 14
caagcatttg catcgctatc a 21

<210> 15
<211> 19
<212> DNA
<213> Mus musculus


<400> 15
aatgcctttt gccggaagt 19

<210> 16
<211> 24
<212> DNA
<213> Mus musculus

<400> 16
acgaattgag aacgtgccca ccgt 24

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3

In re Application of Frederic J. DeSavauge et al. Serial No.: 10/088,950 Filed: October 18, 2000 For: MODULATION OF T CELL DIFFERENTIATION FOR THE TREATMENT OF T HELPER CELL MEDIATED DISEASES	Group Art Unit: NOT KNOWN Examiner: NOT KNOWN <div style="text-align: center;"><small>CERTIFICATE OF MAILING</small> <small>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</small> June 20, 2002  Aida Guilam</div>
--	---

TRANSMITTAL LETTER

BOX SEQUENCES

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:


Transmitted herewith are the following documents:

1. Copy of Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US);
2. Certificate Re: Sequence Listing; Response Under 37 CFR § 1.821(f) and (g);
3. Paper Copy of Sequence Listing and Diskette.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,
GENENTECH, INC.

Date: June 20, 2002

By: 
Atulya R. Agarwal, Ph.D.
Reg. No. 40,887
Telephone No. (650) 225-1739



09157

PATENT TRADEMARK OFFICE

APR 15



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/088,950	Frederic J De Sauvage	P1748R1E

INTERNATIONAL APPLICATION NO.

PCT/US00/28827

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

10/18/2000

Genentech Inc
 1 DNA Way
 South San Francisco, CA 94080-4990

RECEIVED

JUN 17 2002

GENENTECH, INC.
 LEGAL, DEPT.

CONFIRMATION NO. 4737

371 FORMALITIES LETTER



OC00000008234986

Date Mailed: 06/07/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Assignee Statement
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Request for Immediate Examination

CALENDARED/LS

Notice to Comply
 7 AUG 02

DUE DATE

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy

or compact disc, as required by 37 CFR 1.821(c).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

- **APPLICANT MUST PROVIDE:**

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

ANITA D JOHNSON

Telephone: (703) 305-3661

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/088,950	PCT/US00/28827	P1748R1E